Syndax Pharmaceuticals Inc
SNDX
NASDAQ
Biotechnology
$19.84
USD
+0.76 (+3.98%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $1.74B
Volume 1.3M
Revenue
$252.25M
TTM
+222.7%
YoY
Gross Margin
96%
TTM
-0.4%
YoY
Net Income
$-160.05M
TTM
+36.2%
YoY
Operating Cash Flow
$-150.10M
TTM
+37.5%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 38.0 | 45.9 | 68.7 | 64.9 | 72.8 |
YoY Growth | +984.5% | +267.0% | +794.9% | +223.6% | +91.8% |
Cost of Revenue | 1.3 | 2.1 | 2.7 | 2.6 | 3.2 |
Gross Profit | 36.7 | 43.8 | 66.0 | 62.2 | 69.6 |
Selling, General & Administrative | 43.8 | 44.9 | 49.9 | 37.6 | 41.5 |
Other Operating Expenses | 0.0 | 8.3 | -24.2 | 11.8 | 0.0 |
Total Operating Expenses | 106.0 | 109.5 | 104.4 | 108.3 | 109.6 |
Operating Income | -69.4 | -65.7 | -38.4 | -46.0 | -40.0 |
EBITDA | -69.4 | -65.7 | -38.4 | -46.0 | -40.0 |
Other Income / Expense | -0.6 | -0.3 | -34.0 | -0.2 | -0.4 |
Total Other Income / Expense | -2.5 | 5.0 | -29.7 | 3.4 | -9.4 |
Income Before Income Taxes | -71.8 | -60.7 | -68.0 | -42.7 | -49.4 |
Income Taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Net Income | -71.8 | 0.0 | -68.0 | -42.7 | -49.4 |
Consolidated Net Income / Loss | -71.8 | -60.7 | -68.0 | -42.7 | -49.4 |
Net Income Attributable to Common Shareholders | -71.8 | -60.7 | -68.0 | -42.7 | -49.4 |
Basic EPS | -$0.83 | -$0.70 | -$0.78 | -$0.48 | -$0.55 |
Diluted EPS | -$0.83 | -$0.70 | -$0.78 | -$0.48 | -$0.55 |
Basic Shares Outstanding | 86.3M | 86.6M | 87.4M | 88.3M | 89.0M |
Diluted Shares Outstanding | 86.3M | 86.6M | 87.4M | 88.3M | 89.0M |